Vir (VIR) Q2 Revenue Drops 61%
Vir Biotechnology (NASDAQ:VIR), a clinical-stage biotech focused on infectious diseases and immuno-oncology, reported results on August 6, 2025. The company announced a net loss per share of $(0.80) (GAAP). Revenue (GAAP) also fell short, reaching only $1.2 million against estimates of $2.72 million and last year's $3.1 million. The quarter reflected meaningful clinical pipeline advancement, particularly in hepatitis delta and oncology, amidst continued low revenue and large operating losses. Improved cost controls led to reduced expenses, but financial losses persisted. The company closed the period with $892.1 million in cash, cash equivalents, and investments.
Source: Analyst estimates for the quarter provided by FactSet.
Vir Biotechnology is a clinical-stage biotechnology company pursuing treatments for infectious diseases such as chronic hepatitis delta (CHD), chronic hepatitis B (HBV), and various solid tumors. The company leverages advanced antibody discovery, protein engineering, and its proprietary PRO-XTEN™ dual-masked T-cell engager platform to develop immune-based medicines.
Source Fool.com
